For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.
Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.
Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Disclosure information is available at the beginning of the video presentation.
129 Listeners
6 Listeners
31 Listeners
3 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
5 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
316 Listeners
42 Listeners
2 Listeners
115 Listeners
2 Listeners
483 Listeners
55 Listeners
43 Listeners
21 Listeners
322 Listeners
54 Listeners
9 Listeners
166 Listeners
38 Listeners